Targeting CD20: teaching an old dog new tricks

gan Sharman, Jeff P.
Cyhoeddwyd yn Hematology Am Soc Hematol Educ Program (2019)

Effectiveness of Warfarin among Patients with Cancer

gan Rose, Adam J., Sharman, Jeff P., Ozonoff, Al, Henault, Lori E., Hylek, Elaine M.
Cyhoeddwyd 2007

A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera(®)) in Subjects with Previously Un...

gan Sharman, Jeff P., Liberati, Anna Marina, Ishizawa, Kenichi, Khan, Tahira, Robbins, Jeffery, Alcasid, Ann, Rosenberg, Julie Ann, Aurer, Igor
Cyhoeddwyd yn BioDrugs (2019)

B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression

gan Irish, Jonathan M., Myklebust, June H., Alizadeh, Ash A., Houot, Roch, Sharman, Jeff P., Czerwinski, Debra K., Nolan, Garry P., Levy, Ronald
Cyhoeddwyd 2010

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin

gan Horwitz, Steven M., Advani, Ranjana H., Bartlett, Nancy L., Jacobsen, Eric D., Sharman, Jeff P., O’Connor, Owen A., Siddiqi, Tanya, Kennedy, Dana A., Oki, Yasuhiro
Cyhoeddwyd yn Blood (2014)

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

gan Byrd, John C., Flynn, Joseph M., Kipps, Thomas J., Boxer, Michael, Kolibaba, Kathryn S., Carlile, David J., Fingerle-Rowson, Guenter, Tyson, Nicola, Hirata, Jamie, Sharman, Jeff P.
Cyhoeddwyd yn Blood (2016)

An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma

gan Andorsky, David J., Kolibaba, Kathryn S., Assouline, Sarit, Forero‐Torres, Andres, Jones, Vicky, Klein, Leonard M., Patel‐Donnelly, Dipti, Smith, Mitchell, Ye, Wei, Shi, Wen, Yasenchak, Christopher A., Sharman, Jeff P.
Cyhoeddwyd yn Br J Haematol (2018)

Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin

gan Coffey, Greg P., Rajapaksa, Ranjani, Liu, Raymond, Sharpe, Orr, Kuo, Chiung-Chi, Krauss, Sharon Wald, Sagi, Yael, Davis, R. Eric, Staudt, Louis M., Sharman, Jeff P., Robinson, William H., Levy, Shoshana
Cyhoeddwyd 2009

Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States

gan Nabhan, Chadi, Mato, Anthony, Flowers, Christopher R., Grinblatt, David L., Lamanna, Nicole, Weiss, Mark A., Davids, Matthew S., Swern, Arlene S., Bhushan, Shriya, Sullivan, Kristen, Flick, E. Dawn, Kiselev, Pavel, Sharman, Jeff P.
Cyhoeddwyd yn BMC Cancer (2017)

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older

gan Forero-Torres, Andres, Holkova, Beata, Goldschmidt, Jerome, Chen, Robert, Olsen, Gregg, Boccia, Ralph V., Bordoni, Rodolfo E., Friedberg, Jonathan W., Sharman, Jeff P., Palanca-Wessels, Maria Corinna, Wang, Yinghui, Yasenchak, Christopher A.
Cyhoeddwyd yn Blood (2015)

Ublituximab (TG‐1101), a novel glycoengineered anti‐CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymph...

gan Sharman, Jeff P., Farber, Charles M., Mahadevan, Daruka, Schreeder, Marshall T., Brooks, Heather D., Kolibaba, Kathryn S., Fanning, Suzanne, Klein, Leonard, Greenwald, Daniel R., Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., Burke, John M.
Cyhoeddwyd yn Br J Haematol (2016)

Early progression of disease as a predictor of survival in chronic lymphocytic leukemia

gan Ahn, Inhye E., Farber, Charles M., Davids, Matthew S., Grinblatt, David L., Kay, Neil E., Lamanna, Nicole, Mato, Anthony, Nabhan, Chadi, Kiselev, Pavel, Swern, Arlene S., Flick, E. Dawn, Sullivan, Kristen, Sharman, Jeff P., Flowers, Christopher R.
Cyhoeddwyd yn Blood Adv (2017)

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

gan Advani, Ranjana H., Buggy, Joseph J., Sharman, Jeff P., Smith, Sonali M., Boyd, Thomas E., Grant, Barbara, Kolibaba, Kathryn S., Furman, Richard R., Rodriguez, Sara, Chang, Betty Y., Sukbuntherng, Juthamas, Izumi, Raquel, Hamdy, Ahmed, Hedrick, Eric, Fowler, Nathan H.
Cyhoeddwyd yn J Clin Oncol (2013)

The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites

gan Mato, Anthony, Nabhan, Chadi, Lamanna, Nicole, Kay, Neil E., Grinblatt, David L., Flowers, Christopher R., Farber, Charles M., Davids, Matthew S., Swern, Arlene S., Sullivan, Kristen, Flick, E. Dawn, Gressett Ussery, Sarah M., Gharibo, Mecide, Kiselev, Pavel, Sharman, Jeff P.
Cyhoeddwyd yn Blood Adv (2020)

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

gan Byrd, John C., Furman, Richard R., Coutre, Steven E., Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff P., Wierda, William, Zhao, Weiqiang, Heerema, Nyla A., Luan, Ying, Liu, Emily A., Dean, James P., O’Brien, Susan
Cyhoeddwyd yn Clin Cancer Res (2020)

Management of adverse events associated with idelalisib treatment: expert panel opinion

gan Coutré, Steven E., Barrientos, Jacqueline C., Brown, Jennifer R., de Vos, Sven, Furman, Richard R., Keating, Michael J., Li, Daniel, O’Brien, Susan M., Pagel, John M., Poleski, Martin H., Sharman, Jeff P., Yao, Nai-Shun, Zelenetz, Andrew D.
Cyhoeddwyd yn Leuk Lymphoma (2015)

Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry

gan Mato, Anthony R., Barrientos, Jacqueline C., Ghosh, Nilanjan, Pagel, John M., Brander, Danielle M., Gutierrez, Meghan, Kadish, Karen, Tomlinson, Brian, Iyengar, Reethi, Ipe, David, Upasani, Sandhya, Amaya-Chanaga, Carlos I., Sundaram, Murali, Han, Jennifer, Giafis, Nick, Sharman, Jeff P.
Cyhoeddwyd yn Clin Lymphoma Myeloma Leuk (2019)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

gan Coutre, Steven E., Flinn, Ian W., de Vos, Sven, Barrientos, Jacqueline C., Schreeder, Marshall T., Wagner-Johnson, Nina D., Sharman, Jeff P., Boyd, Thomas E., Fowler, Nathan, Dreiling, Lyndah, Kim, Yeonhee, Mitra, Siddhartha, Rai, Kanti, Leonard, John P., Furman, Richard R.
Cyhoeddwyd yn Hemasphere (2018)

Real‐world clinical experience in the Connect(®) chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres

gan Mato, Anthony, Nabhan, Chadi, Kay, Neil E., Weiss, Mark A., Lamanna, Nicole, Kipps, Thomas J., Grinblatt, David L., Flinn, Ian W., Kozloff, Mark F., Flowers, Christopher R., Farber, Charles M., Kiselev, Pavel, Swern, Arlene S., Sullivan, Kristen, Flick, E. Dawn, Sharman, Jeff P.
Cyhoeddwyd yn Br J Haematol (2016)

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma

gan de Vos, Sven, Wagner-Johnston, Nina D., Coutre, Steven E., Flinn, Ian W., Schreeder, Marshall T., Fowler, Nathan H., Sharman, Jeff P., Boccia, Ralph V., Barrientos, Jacqueline C., Rai, Kanti R., Boyd, Thomas E., Furman, Richard R., Kim, Yeonhee, Godfrey, Wayne R., Leonard, John P.
Cyhoeddwyd yn Blood Adv (2016)